equipocesca

It seems that Teva’s commercial strategy includes promoting fremanezumab (Ajovy) to the general public (direct-to-consumer).  Vall d’Hebron Hospital (Barcelona, Spain) supports and presents as a novelty something that “offers nothing new”.  Such promotion is clearly prohibited by Spanish and European legislation.  It is also accompanied by an incredible and constant “apparatus” of pressure on those [...]

• 

Teva employs multiple mechanisms to maintain its business, from corruption to direct publicity, including the manipulation of opinion leaders (professionals and patients). Nothing compares to the impact of someone who suffers and “plays” in favor of Teva and against science and ethics. A personal narrative of suffering negates all the work that underpins rational and [...]

• 

Duchenne muscular dystrophy is a neurodegenerative disease with no current cure. In 2014, the FDA and EMA evaluated a new drug for this condition: ataluren. Ataluren was not approved by the FDA due to a lack of efficacy in Duchenne muscular dystrophy, while the EMA granted conditional approval. After marketing authorization in the EU, the [...]

• 

Leaders like Trump and Netanyahu are not an aberration but the expected expression of a regime where mediation collapses, where the state merges with the leader’s desires, and where obscenity becomes a legitimate political response. Thus, the “madness” of accusing of terrorism anyone who writes or shouts “Long live free Palestine!”, or the Big Brother-style [...]

• 

The debate on the coercive vaccination is raised many times with the example of the acceptance of the implementation of the mandatory use of  seat belts in motor vehicles. It is a very popular approach usually led by those who lack scientific training in vaccines. Seat belts are no vaccines, and motor vehicles are not [...]

• 

During the climacteric period, before, during and after the menopause, hot flushes are common. In general they can be endured without great discomfort and subside with time, but there are cases of great intensity and persistence. This paper discusses the marketing of Veoza (fezolinetant) for the relief of hot flushes. The issue is that it [...]

• 

In occasion of the ongoing trilogues on the European Medicines Agency (EMA) extended mandate, Members of the European Alliance for Responsible R&D and Affordable Medicines urge the Council to ensure the new Regulation enhances clinical trial transparency and upholds good governance.    As explained in a letter published today, it is crucial that information on [...]

•